Navigation Links
$1.5 Million Grant to Yale for Narcolepsy-Neurotransmitter Study

Yale School of Medicine researchers have received a $1.5 million grant from the National Institutes of Health (NIH) to study neurons// that play a major role in narcolepsy.

Narcolepsy is a neurodegenerative disease characterized by daytime sleepiness. The NIH grant will further Yale research into narcolepsy and other disorders linked to neurons that produce the peptide hypocretin.

“The activity of these hypocretin cells is important for enhancing cognitive arousal and resisting sleep, and they may also play a role in anxiety and body weight regulation,” said the principal investigator, Anthony van den Pol, neurosurgery professor.

He said neurons send out long fibers, or axons, to other nerve cells and release either an inhibitor or excitatory neurotransmitter onto their target cells. A small number of these neurons make and secrete the transmitter hypocretin.

Hypocretin neurons actually make two neurotransmitters, hypocretin and dynorphin. The results of Van den Pol’s recent work, published in the Journal of Neuroscience, shows that these two transmitters, or peptides, have actions that oppose each other. Hypocretin increases the excitability of other nerve cells, whereas dynorphin inhibits the activity.

Van den Pol and first author, Ying Li, an associate research scientist, wondered what cellular value opposing neurotransmitters might have. They found that different target neurons in the brain show different responses to co-stimulation by the two peptides.

They came to this finding by using whole cell patch clamp recording, in which an ultra-thin glass pipette, like a very small straw, is used to record the electrical activity caused by movement of ions through channels in single nerve cells.

Van den Pol said that these neurotransmitters had different effects on different cell types. One target, MCH neurons, were excited by hypocretin but inhibited by dynorphin.

“This mi ght suggest that the two neurotransmitters would simply cancel the actions of each other,” van den Pol said. “But, interestingly, in the continuing presence of both neurotransmitters, the inhibitory MCH cell response to dynorphin rapidly declined, whereas the excitatory response to hypocretin persisted.” Therefore, he said, low levels of release of both transmitters might favor inhibition, whereas high levels of release might swing the tide over to excitation and increase cognitive arousal.

However, on another target, NPY neurons, hypocretin directly excited the cells, byt dynorphin had little direct effect. Rather, dynorphin contributed to increased nerve cell activity by reducing the release of inhibitory neurotransmitters onto the NPY cells. In this case, the transmitters act synergistically to excite the NPY cell.

Under the NIH grant, van den Pol and colleagues will study the effects of both naturally occurring neuroactive compounds, as well as man made drugs, to determine how they influence the hypocretin cells, and, ultimately, cognitive arousal.

Source-YALE UniversitySRM
'"/>




Related medicine news :

1. Drug May Make Breathing Easier for Millions
2. Over Six Million HIV Infected People In South Africa- Finds A Survey
3. Tanzanian Government Sanctions $20 Million For AIDS Arug
4. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
5. Number Of Babies Born Prematurely Nears Historic Half Million Mark In US
6. Proper Validation of Generic Drugs Could Save Millions of AIDS Patients
7. An Estimated 150 Million Indians Suffer From Arthritis
8. Acute Shortage Of Neurosurgeons In India: One Surgeon For Every 1 Million!
9. India To Procure 1 Million Doses Of Tamiflu
10. Global Warming Could Cause 5 Million Illnesses: WHO
11. Australia earmarks $74 Million to Fight Bird Flu
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... 24, 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s ... of his paramedic experiences. Schanssema describes the tragedies he saw, as well as his ... them. , Schanssema, initially unsure of the career path he wanted to take, found ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced ... the Chairman of the Management Committee when IFN was originally formed in 2002 where ... investor/owners and development of the business plan. He became the first paid employee ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning sunscreen ... Fondo of Marin. For the second year in a row, cyclists will stay ... “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased ... KLS is a longtime supporter of the event. , "We are pleased that KLS ... Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record of ...
(Date:2/23/2017)... California (PRWEB) , ... February 23, 2017 , ... ... Sports Development will host a diverse symposium on “Doping in Sport: ... Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be held ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Februar 2017 LG Innotek hat heute die ... Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... zwischen 200 und 280 nm und eignet sich damit für ... ihre DNA zerstört. Das Produkt von LG Innotek erzeugt ... ...
(Date:2/23/2017)... 23, 2017 Nevro Corp. (NYSE: NVRO), a global ... the treatment of chronic pain, today reported financial results for ... 2016 Accomplishment & Highlights: ... an increase of 228% as reported, over the prior year ... increase of 612% over the prior year ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
Breaking Medicine Technology: